Sign In
Buy TMDX
$69.69
+1.24 (+1.81%)
At Close: Jun 03, 2026
This Healthcare Infrastructure Stock Is Risky, But the Upside Looks Huge
06:00pm, Tuesday, 02'nd Jun 2026
TransMedics (TMDX +1.19%) has been hit hard as investors question margins, spending, and execution. But beneath the sell-off, the company's Organ Care System, aviation network, and National OCS Progra
Reasons to Retain TransMedics Stock in Your Portfolio for Now
02:01pm, Thursday, 28'th May 2026
TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.
TransMedics: Despite Earnings Miss, Growth Story Remains Intact
01:28pm, Monday, 25'th May 2026
TransMedics remains a 'Strong Buy' despite a 50% stock decline and Q1 2026 earnings miss, supported by robust long-term growth initiatives. TMDX's portfolio expansion includes CHOPS as a complementary
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Thursday, 21'st May 2026
ANDOVER, Mass., May 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st
TransMedics to Present at the William Blair 46th Annual Growth Stock Conference
04:05pm, Tuesday, 19'th May 2026
ANDOVER, Mass., May 19, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st
TransMedics: Cheaper, But Still Priced For Perfection
07:56pm, Wednesday, 06'th May 2026
TransMedics Group, Inc. remains a Sell as its valuation still bakes in near-perfect execution, despite the stock being nearly 40% cheaper since October. TMDX's valuation implies sustaining some combin
TMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins Fall
12:55pm, Wednesday, 06'th May 2026
TransMedics' Q1 revenues rise 21% on strong OCS demand, but a sharp EPS miss and margin pressure send shares down despite continued logistics growth.
TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call Transcript
08:41pm, Tuesday, 05'th May 2026
TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call Transcript
TransMedics (TMDX) Reports Q1 Earnings: What Key Metrics Have to Say
08:01pm, Tuesday, 05'th May 2026
While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compa
TransMedics (TMDX) Q1 Earnings and Revenues Miss Estimates
07:10pm, Tuesday, 05'th May 2026
TransMedics (TMDX) came out with quarterly earnings of $0.3 per share, missing the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.7 per share a year ago.
TransMedics Reports First Quarter 2026 Financial Results
04:05pm, Tuesday, 05'th May 2026
ANDOVER, Mass., May 5, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta
Proposed strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, intended to lay the foundation for TransMedics to establish a dedicated organ transplantation
TransMedics: Revolutionizing The Organ Transplant Market While Trading At A Discount
09:56am, Friday, 24'th Apr 2026
TransMedics Group is a strong buy, leveraging its technological and logistical moat in organ transport, with OCS and NOP programs driving sector outperformance. TMDX trades at a 39x Non-GAAP PE and 5.
Unveils New Controlled Hypothermic Organ Preservation System (CHOPS) to Expand its Product Portfolio and to Facilitate Enrollment in Control Arms of OCS ENHANCE Heart Part B and OCS DENOVO Lung Clinic
TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026
04:05pm, Tuesday, 21'st Apr 2026
ANDOVER, Mass., April 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-
